Aurinia Pharmaceuticals Q1 2025 10-Q Filed
Ticker: AUPH · Form: 10-Q · Filed: May 12, 2025 · CIK: 1600620
| Field | Detail |
|---|---|
| Company | Aurinia Pharmaceuticals Inc. (AUPH) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Aurinia Pharma Q1 2025 10-Q is in. Revenue and balance sheet details are out.
AI Summary
Aurinia Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenue from product sales and license/collaboration/royalty agreements for the first quarter of 2025 and 2024. Financial details regarding common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings are presented as of March 31, 2025, and December 31, 2024.
Why It Matters
This filing provides investors with the latest financial performance and position of Aurinia Pharmaceuticals, crucial for understanding the company's ongoing operations and financial health.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Aurinia is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025 Q1 — Reporting Period (First quarter of 2025)
- 2024-12-31 — Previous Year End (Balance sheet comparison date)
- 2025-03-31 — Current Quarter End (Balance sheet comparison date)
Key Players & Entities
- Aurinia Pharmaceuticals Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250512 (date) — Filing date
FAQ
What were Aurinia Pharmaceuticals' total revenues for the first quarter of 2025?
The filing indicates revenue from product sales and license/collaboration/royalty revenue for the period January 1, 2025, to March 31, 2025, but specific dollar amounts are not detailed in this header information.
How does the company's financial position at March 31, 2025, compare to December 31, 2024?
The 10-Q provides data for common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings as of both March 31, 2025, and December 31, 2024, allowing for comparison.
What is the primary business of Aurinia Pharmaceuticals Inc. according to the filing?
Aurinia Pharmaceuticals Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
When was this 10-Q form filed with the SEC?
This 10-Q form was filed on May 12, 2025.
What specific types of revenue are mentioned for the first quarter of 2025?
The filing mentions 'LicenseCollaborationAndRoyaltyRevenueMember' and 'ProductMember' as sources of revenue for the first quarter of 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Aurinia Pharmaceuticals Inc. (AUPH).